BioMarin Pharmaceutical's total assets for Q1 2025 were $7.15B, an increase of 2.26% from the previous quarter. BMRN total liabilities were $1.35B for the fiscal quarter, a 1.70% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.